MODERN OPPORTUNITIES OF BONE ANABOLIC THERAPY OF OSTEOPOROSIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Osteoporosis (OP) is a serious medical and social problem, which is attributable with the high prevalence of this disease. The main clinical manifestation of OP and one of the leading risk factors for subsequent fracture is a bone fracture after minor injury. Currently, there are effective treatments of OP, combining non-pharmacological approaches with the use of modern antiosteoporotic drugs. Timely medical interventions can reduce the risk of osteoporotic fractures and improve the quality of life of the patient. Teriparatide is high effective bone anabolic drug that increases bone mineral density in patients with high risk of low-energy fractures and provides new opportunities for solving the main goal of treatment of the disease - reducing the risk of fractures of various localizations.

Full Text

Restricted Access

About the authors

E. V Biryukova

FSBEIHPE MSMSU n.a. A.I. Evdokimov of RMH

Email: lena@obsudim.ru
MD, Prof., Director of Studies at the Department of Endocrinology and Diabetology Moscow

References

  1. Инструкции по медицинскому применению терипаратида. Регистрационный номер: П № 015927/01 от 12.05.2011.
  2. Лесняк О.М. Современные подходы к диагностике и лечению остеопороза. Фарматека. Остеопороз. 2012;1(12):40-4.
  3. Риггз Б.Л., Мелтон III Л.Д. Остеопороз. Этиология, диагностика, лечение. М., 2000.
  4. Bouvard B., Audran M., Legrand E., Chappard D. Ultrastructural characteristics of glucocorticoidinduced osteoporosis. Osteoporosis International. 2009;20:1089-92.
  5. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 2007;18:1319-28.
  6. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., Black D. Risk of mortality following clinical fractures. Osteoporos. Int. 2000;11:556-61.
  7. Davidson M.R. Pharmacotherapeutics for osteoporosis prevention and treatment. J. Midwifery Womens Health. 2003;48:39-52.
  8. Dempster D.W. Osteoporosis and the burden of osteoporosis-related fractures. Am. J. Manage Care. 2011;17(Suppl. 6):164-69.
  9. Dobnig H., Turner R.T Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136(8):3632-38.
  10. Fahrleitner-Pammer A., Langdahl B.L., Marin F., Jakob F., Karras D., Barret A., Ljunggren O., Walsh J.B., Rajzbaum G., Barker C., Lems W.F. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos. int. 2011;22:2709-19.
  11. Heaney R.P. Advances in therapy for osteoporosis. Clin. Med. Res. 2003;1(2):93-9.
  12. Hock J.M. Anabolic actions of PTH in the skeletons of animals. J. Musculoskelet Neuronal. interact. 2001;2(1):33-47.
  13. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 2003;18(11):1932-41.
  14. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. invest. 1999;104(4):439-46.
  15. JinL.,Briggs S.L., Chandrasekhar S., Chirgadze N.Y., Clawson D.K., Schevitz R.W., Smiley D.L., Tashjian A.H., Zhang F Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution. J. Biol. Chem. 2000;275(35):27238-44.
  16. Kanis J.A., Johnell O., De Laet C., Johansson H., Oden A., Delmas P., Eisman J., Fujiwara S., Garnero P., Kroger H., McCloskey E.V., Mellstrom D., Melton L.J., Pols H., Reeve J., Silman A., Tenenhouse A. A meta-analysisof previous fracture and subsequent fracture risk. Bone. 2004;35(2):375-82.
  17. Lawrence V.A., Hilsenbeck S.G., Noveck H., Poses R.M., Carson J.L. Medical complications and outcomes after hip fracture repair. Arch. intern. Med. 2002;162:2053-57.
  18. Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B., Licata A., Benhamou L., Geusens P/, Flowers K., Stracke H., Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA. 200;285(3):320-23.
  19. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., Chandrasekhar S., Martin T.J., Onyia J.E. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142(9): 4047-54.
  20. Mauck K.F., Clarke B.L. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin. Proc. 2006; 81(5):662-72.
  21. National institutes of Health Consensus Development Panel on Osteoporosis Treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-95.
  22. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., 7Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001;344(19):1434-41.
  23. Nguyen T.V., Center J.R., Eisman J.A. Osteoporosis: underdiagnosed and undertreated. Med. J. 2004; 180(5):18-22.
  24. Niall H.D., Sauer R.T., Jacobs J.W., Keutmann H.T., Segre G.V., O'Riordan J.L., Aurbach G.D., Potts J.T. The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc. Natl. Acad. Sci. USA. 1974;71(2):384-88.
  25. Painter S.E., Kleerekoper M., Camacho P.M. Secondary osteoporosis: a review of the recent evidence. Endocr. Pract. 2006;12(4):436-45.
  26. Parfitt A.M., Mathews C.H., Villanueva A.R., Kleerekoper M., Frame B., Rao D.S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. invest. 1983;72(4):1396-409.
  27. Podbesek R., Edouard C., Meunier P.J., Parsons J.A., Reeve J., Stevenson R.W., Zanelli J.M. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology. 1983;112(3):1000-6.
  28. Pohl G., Wang J., Scheele W.H. Effect of duration of teriparatide therapy on nonvertebral fracture risk. Arthritis Rheum. 2003; 48(Suppl. 9):234.
  29. Riggs B.L., Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 2005;20(2):177-84.
  30. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., Dalsky G.P., Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2007;357(20):2028-39.
  31. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology. 2008;47(Suppl. 4):2-8.
  32. Tam C.S., Heersche J.N., Murray T.M., Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982;110(2):50-12.
  33. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 2000;15:993-1000.
  34. Van Staa T., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis. Osteopros int. 2002;13:777-87.
  35. Woolf A.D. An update on glucocorticoid-induced osteoporosis. Current. Opinion in Rheumatology. 2007;19:370-75.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies